Stereotactic Radiosurgery for Ependymoma in Pediatric and Adult Patients: A Single-Institution Experience.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
10
11
2023
accepted:
12
03
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Ependymoma is commonly classified as World Health Organization grade 2 with the anaplastic variant categorized as grade 3. Incomplete resection or anaplastic features can result in unfavorable outcomes. Stereotactic radiosurgery (SRS) provides a minimally invasive approach for recurrent ependymomas. Our study investigates the efficacy and safety of SRS for grade 2 and 3 ependymomas in pediatric and adult populations. We conducted a retrospective analysis on 34 patients with 75 ependymomas after CyberKnife SRS between 1998 and 2023. Fourteen were pediatric (3-18 years), and 20 were adult (19-75 years) patients. The median age was 21 years, and the median tumor volume was 0.64 cc. The median single-fraction equivalent dose was 16.6 Gy, with SRS administered at 77% of the median isodose line. After a median follow-up of 42.7 months (range: 3.8-438.3), 22.7% of ependymomas progressed. The 5-year local tumor control rate was 78.1%, varying between 59.6% and 90.2% for children and adults, with grade 2 at 85.9% compared with 58.5% for grade 3 tumors. The 5-year overall survival rate was 73.6%, notably higher in adults (94.7%) than in children (41%), and 100% for grade 2 but decreased to 35.9% for grade 3 patients. The 5-year progression-free survival rate was 68.5%, with 78.3% and 49.2% for adults and children, respectively, and a favorable 88.8% for grade 2, contrasting with 32.6% for grade 3 patients. Symptom improvement was observed in 85.3% of patients. Adverse radiation effects occurred in 21.4% of pediatric patients. Our study supports SRS as a viable modality for pediatric and adult patients with grade 2 and 3 ependymomas. Despite lower local tumor control in pediatric and grade 3 cases, integrating SRS holds promise for improved outcomes. Emphasizing careful patient selection, personalized treatment planning, and long-term follow-up is crucial for optimal neurosurgical outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Ependymoma is commonly classified as World Health Organization grade 2 with the anaplastic variant categorized as grade 3. Incomplete resection or anaplastic features can result in unfavorable outcomes. Stereotactic radiosurgery (SRS) provides a minimally invasive approach for recurrent ependymomas. Our study investigates the efficacy and safety of SRS for grade 2 and 3 ependymomas in pediatric and adult populations.
METHODS
METHODS
We conducted a retrospective analysis on 34 patients with 75 ependymomas after CyberKnife SRS between 1998 and 2023. Fourteen were pediatric (3-18 years), and 20 were adult (19-75 years) patients. The median age was 21 years, and the median tumor volume was 0.64 cc. The median single-fraction equivalent dose was 16.6 Gy, with SRS administered at 77% of the median isodose line.
RESULTS
RESULTS
After a median follow-up of 42.7 months (range: 3.8-438.3), 22.7% of ependymomas progressed. The 5-year local tumor control rate was 78.1%, varying between 59.6% and 90.2% for children and adults, with grade 2 at 85.9% compared with 58.5% for grade 3 tumors. The 5-year overall survival rate was 73.6%, notably higher in adults (94.7%) than in children (41%), and 100% for grade 2 but decreased to 35.9% for grade 3 patients. The 5-year progression-free survival rate was 68.5%, with 78.3% and 49.2% for adults and children, respectively, and a favorable 88.8% for grade 2, contrasting with 32.6% for grade 3 patients. Symptom improvement was observed in 85.3% of patients. Adverse radiation effects occurred in 21.4% of pediatric patients.
CONCLUSION
CONCLUSIONS
Our study supports SRS as a viable modality for pediatric and adult patients with grade 2 and 3 ependymomas. Despite lower local tumor control in pediatric and grade 3 cases, integrating SRS holds promise for improved outcomes. Emphasizing careful patient selection, personalized treatment planning, and long-term follow-up is crucial for optimal neurosurgical outcomes.
Identifiants
pubmed: 38785440
doi: 10.1227/neu.0000000000002979
pii: 00006123-990000000-01176
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.
Références
Shi S, Jin MC, Koenig J, et al. Stereotactic radiosurgery for pediatric and adult intracranial and spinal ependymomas. Stereotact Funct Neurosurg. 2019;97(3):189-194.
Kudo H, Oi S, Tamaki N, Nishida Y, Matsumoto S. Ependymoma diagnosed in the first year of life in Japan in collaboration with the International Society for Pediatric Neurosurgery. Childs Nerv Syst. 1990;6(7):375-378.
Osborn AG, Louis DN, Poussaint TY, Linscott LL, Salzman KL. The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol. 2022;43(7):928-937.
Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD. Adjuvant stereotactic radiosurgery after resection of intracranial hemangiopericytomas. Int J Radiat Oncol Biol Phys. 2008;72(5):1333-1339.
Salazar OM, Castro-Vita H, VanHoutte P, Rubin P, Aygun C. Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg. 1983;59(4):652-659.
Lo SS, Chang EL, Sloan AE. Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in the management of intracranial ependymoma. Expert Rev Neurother. 2006;6(4):501-507.
Goldwein JW, Glauser TA, Packer RJ, et al. Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer. 1990;66(3):557-563.
Aggarwal R, Yeung D, Kumar P, Muhlbauer M, Kun LE. Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiother Oncol. 1997;43(3):269-273.
Yoo KH, Park DJ, Choi JH, et al. Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases. Front Oncol. 2023;13:1223599.
Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD. Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery. 2009;64(2):279-288; discussion 287-288.
Kano H, Yang H-C, Kondziolka D, et al. Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr. 2010;6(5):417-423.
Sato K, Baba Y, Inoue M, Omori R. Radiation necrosis and brain edema association with CyberKnife treatment. Acta Neurochir Suppl. 2003;86:513-517.
Gibbs IC, Patil C, Gerszten PC, Adler JR Jr, Burton SA. Delayed radiation-induced myelopathy after spinal radiosurgery. Neurosurgery. 2009;64(2 Suppl):A67-A72.
Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008;71(1):87-97.
Gibbs IC. Frameless image-guided intracranial and extracranial radiosurgery using the Cyberknife robotic system. Cancer Radiother. 2006;10(5):283-287.
Ryu SI, Kim DH, Chang SD. Stereotactic radiosurgery for hemangiomas and ependymomas of the spinal cord. Neurosurg Focus. 2003;15(5):e10.
Hodgson DC, Goumnerova LC, Loeffler JS, et al. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys. 2001;50(4):929-935.
Jawahar A, Kondziolka D, Flickinger JC, Lunsford LD. Adjuvant stereotactic radiosurgery for anaplastic ependymoma. Stereotact Funct Neurosurg. 1999;73(1-4):23-30.
Agarwal S, Stevenson ME, Sughrue ME, Wartchow EP, Mierau GW, Fung K-M. Features of intraventricular tanycytic ependymoma: report of a case and review of literature. Int J Clin Exp Pathol. 2014;7(6):3399-3407.
Weprin BE, Hall WA, Cho KH, Sperduto PW, Gerbi BJ, Moertel C. Stereotactic radiosurgery in pediatric patients. Pediatr Neurol. 1996;15(3):193-199.
Grabb PA, Lunsford LD, Albright AL, Kondziolka D, Flickinger JC. Stereotactic radiosurgery for glial neoplasms of childhood. Neurosurgery. 1996;38(4):696-702; discussion 701-702.
Hirato M, Nakamura M, Inoue HK, et al. Gamma Knife radiosurgery for the treatment of brainstem tumors. Stereotact Funct Neurosurg. 1995;64(Suppl 1):32-41.
Loeffler JS, Rossitch E Jr, Siddon R, Moore MR, Rockoff MA, Alexander E 3rd. Role of stereotactic radiosurgery with a linear accelerator in treatment of intracranial arteriovenous malformations and tumors in children. Pediatrics. 1990;85(5):774-782.
Kresbach C, Neyazi S, Schüller U. Updates in the classification of ependymal neoplasms: the 2021 WHO Classification and beyond. Brain Pathol. 2022;32(4):e13068.
Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554-568.
Vernimmen FrederikJAI, Slabbert JP. Assessment of the alpha/beta ratios for arteriovenous malformations, meningiomas, acoustic neuromas, and the optic chiasma. Int J Radiat Biol. 2010;86(6):486-498.
Joiner MC, van der Kogel AJ, eds. Basic Clinical Radiobiology. 5th ed. CRC Press; 2018.
Kano H, Su Y-H, Wu H-M, et al. Stereotactic radiosurgery for intracranial ependymomas: an International Multicenter Study. Neurosurgery. 2019;84(1):227-234.
Liu A-L, Wang Z-C, Sun S-B, Wang M-H, Luo B, Liu P. Gamma knife radiosurgery for residual skull base chordomas. Neurol Res. 2008;30(6):557-561.
Elibe E, Boyce-Fappiano D, Ryu S, et al. Stereotactic radiosurgery for primary tumors of the spine and spinal cord(†). J Radiosurg SBRT. 2018;5(2):107-113.
Lobón MJ, Bautista F, Riet F, et al. Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. Springerplus. 2016;5(1):879.
Murai T, Sato K, Iwabuchi M, et al. Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. Jpn J Radiol. 2016;34(3):211-218.
Hoffman LM, Donson AM, Nakachi I, et al. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 2014;127(5):731-745.
Stauder MC, Ni Laack N, Ahmed KA, Link MJ, Schomberg PJ, Pollock BE. Stereotactic radiosurgery for patients with recurrent intracranial ependymomas. J Neuro-Oncol. 2012;108(3):507-512.
Endo H, Kumabe T, Jokura H, Shirane R, Tominaga T. Stereotactic radiosurgery for nodular dissemination of anaplastic ependymoma. Acta Neurochir (Wien). 2004;146(3):291-298.
Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2005;61(2):387-391.
Benzil DL, Saboori M, Mogilner AY, Rocchio R, Moorthy CR. Safety and efficacy of stereotactic radiosurgery for tumors of the spine. J Neurosurg. 2004;101(Suppl 3):413-418.
Combs SE, Kelter V, Welzel T, et al. Influence of radiotherapy treatment concept on the outcome of patients with localized ependymomas. Int J Radiat Oncol Biol Phys. 2008;71(4):972-978.
Acquaye AA, Vera E, Gilbert MR, Armstrong TS. Clinical presentation and outcomes for adult ependymoma patients. Cancer. 2017;123(3):494-501.
Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 2016;18(7):902-913.
Stafford SL, Pollock BE, Foote RL, Gorman DA, Nelson DF, Schomberg PJ. Stereotactic radiosurgery for recurrent ependymoma. Cancer. 2000;88(4):870-875.
Rudà R, Bruno F, Pellerino A, Soffietti R. Ependymoma: evaluation and management updates. Curr Oncol Rep. 2022;24(8):985-993.
Soto CJ, Novick SD, Naga Laxmi Poojita A, Khan S, Khan MW, Holder SS. Spinal myxopapillary ependymoma: a rare case and review of management strategies. Cureus. 2023;15(5):e39381.
Abdel-Baki MS, Hanzlik E, Kieran MW. Multidisciplinary pediatric brain tumor clinics: the key to successful treatment? CNS Oncol. 2015;4(3):147-155.
Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199.